Atlas Trials

Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

Clinical trial NCT04241523 · UNKNOWN

Trial details

NCT number
NCT04241523
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2020-01-01
Primary completion
2021-10-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.